CN102145006A - Depression resistance application of panaxoside Ppt - Google Patents
Depression resistance application of panaxoside Ppt Download PDFInfo
- Publication number
- CN102145006A CN102145006A CN2010101075238A CN201010107523A CN102145006A CN 102145006 A CN102145006 A CN 102145006A CN 2010101075238 A CN2010101075238 A CN 2010101075238A CN 201010107523 A CN201010107523 A CN 201010107523A CN 102145006 A CN102145006 A CN 102145006A
- Authority
- CN
- China
- Prior art keywords
- ppt
- depression
- ginsenoside
- ginsenoside ppt
- panaxoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Steroid Compounds (AREA)
Abstract
The invention discloses new application of panaxoside Ppt serving as metabolin of panaxoside Rg1 to the preparation of medicaments for preventing and treating depression. Experiments prove that the panaxoside Ppt has obvious curative effect, quick response and small toxic and side effects on the depression resistance, is a safe, efficient and stable anti-depression medicament, is suitable for industrial production and is easy to popularize. The panaxoside Ppt provides a new medicinal source for the prevention and treatment of depression and complications, impediment or diseases thereof.
Description
Technical field
The present invention relates to the medicine or the health food of a kind of prevention, alleviation and/or treatment affective disorders nervous system disease, particularly a kind of antidepressant drug or health food.
Background technology
Depression (depression) is the main type of affective disorders (mood disorders), be a kind of low with remarkable and persistent mental state be the syndrome of principal character.Depression is the able-bodied commonly encountered diseases of harm humans, frequently-occurring disease, is a global main mental disease.
Depression mainly shows as depressed, and interest lowers, pessimism, and retardation of thinking lacks initiative, and self-accusation is from crime, and diet, sleep are poor, worry oneself to suffer from various diseases, feel whole body many places discomfort, and suicidal thought and behavior can appear in severe patient.
Depression is the highest disease of psychiatric department homicide rate.The depression sickness rate is very high, among almost per 5 adults 1 patients with depression is just arranged, so it is called as the flu in the psychiatry.Depression has become second important diseases that causes serious burden in the global disease to the mankind at present, and to the misery that patient and family members thereof cause, the loss that society is caused is that other diseases is incomparable.The main cause that causes this situation is that society lacks correct understanding to depression, and prejudice makes the patient be reluctant that psychiatric department goes to a doctor.In China, only there is 5% patients with depression to accept treatment, a large amount of patients can not get diagnosis and treatment timely, and sb.'s illness took a turn for the worse, even the serious consequence of committing suiside occurs.On the other hand, because the common people lack the knowledge of relevant depression, the person thinks it is to be disgruntled by mistake to the depressive symptom occurring, can not give due understanding and emotion support, and the patient is caused bigger mental pressure, and the state of an illness is further worsened.
The seriousness day by day of depression fashion trend, the patient has caused the generally attention of countries in the world because of the decline of psychological diathesis due to the mental disorder with to the infringement of social function.The demand of antagonism down increases day by day in the world wide, and this quasi drugs world market sales volume every year is with 16.2% speed increment in recent years.The development of the control of depression and antidepressant new drug has become one of current international the world of medicine forward position hot research problem.
The Therapeutic Method of depression is a lot, as psychology treatment, sleep deprivation treatment, phototherapy and electric convulsive treatment etc., but at present still based on Drug therapy, is aided with the psychotherapy simultaneously.Present antidepressant main flow medicine has five big classes substantially: serotonin reuptake inhibitors (SSRIs) optionally, norepinephrine and specific serotonin reuptake inhibitors (NaSSA), tricyclic antidepressants counter inhibitor (TCAs), monoamine oxidase, MAO down (MAOIs) and serotonin and NRI (SNARI).These medicines all have untoward reaction in various degree, as drowsiness, blurred vision, hypertension, convulsions and hyposexuality etc., influencing it extensively promotes the use of, and these medicines are limit owing to himself defective, have that antidepressant spectrum is narrower, toxic and side effects is big, price is high, easily recur, be not suitable for problem such as the property nursed one's health treatment after the drug withdrawal, so had a strong impact on their clinical use.
Extract from traditional drugs in recent years that to have efficient antidepressant monomer medicine research increasing, become a kind of trend of international pharmacy industry exploitation antidepressant drug, for example German Herba Hyperici perforati (Herba Hyperici perforati) the extract hypericin of researching and developing, now listed the antidepressant main flow medicine of countries such as America and Europe in, but it is applicable to the slight and moderate depressive patients of treatment, the severe curative effect of depression is not shown, exist some potential safety hazards yet.
The inventor finds in the process of research ginsenoside Rg1 antidepressant function: the metabolite ginsenoside Ppt of ginsenoside Rg1 is easier to produce significant antidepressant effect by blood brain barrier, and efficacy stability, side effect is little, antidepressant drug and health food with its preparation have better quality controllability and universality, for serious depression definite curative effect are arranged also.
Ginsenoside Ppt is the metabolite of ginsenoside Rg1, and its molecular formula is C
30H
52O
4, molecular weight is 476.73, molecular structure is suc as formula shown in (I).
Modern pharmacological research shows that the metabolite ginsenoside Ppt of ginsenoside Rg1 has the purposes of anti-cognition, learning functionality obstacle, can be used for preparing the medicine and the health food that improve cognitive function and learning and memory function, but the application in preparation prevention and treatment depression medicine yet there are no report so far about ginsenoside Ppt.
Summary of the invention
Primary and foremost purpose of the present invention is the problem that exists at above-mentioned prior art, ginsenoside Ppt, the anti-affective disorders of ginsenoside Ppt compositions are provided, particularly antidepressant performance and effect, and ginsenoside Ppt or its pharmaceutically acceptable salt or its solvate are provided or contain the new pharmaceutical usage of compositions of effective dose ginsenoside Ppt, promptly in treatment, conditioning and the medicine of prevention depression, the new application in the health food.
For achieving the above object, one aspect of the present invention provides a kind of ginsenoside Ppt application in preparation prevention, alleviation and/or treatment affective disorders disease medicament or health product.
Wherein, described affective disorders disease is mainly depression.
Wherein, the metabolite ginsenoside Ppt of Radix Ginseng Saponin Rg1 of the present invention can prepare by commercially available or known method.
Wherein, described ginsenoside Ppt purity 〉=50%, be preferably 〉=80%, more preferably 〉=90%.
Wherein, the content of described ginsenoside Ppt 〉=50%, be preferably 〉=80%, more preferably 〉=90%.
Wherein, described medicine is formed by ginsenoside Ppt and pharmaceutically acceptable carrier or with other antidepressant chemical compound.
Particularly, pharmaceutically acceptable carrier is used for this purpose by sanitarian approval and usually as the non-active ingredient of medicament.The compilation of relevant pharmaceutically acceptable carrier can (Handbook of Pharmaceutical excipients, be edited by A.Wade and P.J.Weller by the 2nd edition in " handbook of pharmaceutical excipients "; American Pharmaceutical Association publishes, Washington and ThePharmaceutical Press, London, 1994) etc. find in the reference book.
Especially, described carrier comprises excipient, as starch, water etc.; Lubricant is as magnesium stearate etc.; Disintegrating agent is as microcrystalline Cellulose etc.; Filler is as lactose etc.; Binding agent is as pregelatinized Starch, dextrin etc.; Sweeting agent; Antioxidant; Antiseptic, correctives, spice etc.;
Wherein, described medicine is by through gastrointestinal administration and non-through the gastrointestinal administration administration.
Particularly, described non-through gastrointestinal administration approach selection drug administration by injection, respiratory tract administration, percutaneous drug delivery, mucosa delivery or cavity/canal drug administration.
Wherein, described medicine exists with forms such as tablet, capsule, pill, powder, granule, syrup, solution, injection, spray, aerosol, patches.
Wherein, non-through gastrointestinal administration medicament selection injection, spray, aerosol, patch etc.
Particularly, described through gastrointestinal administration preparation selection tablet, capsule, powder, granule, pill, solution or syrup etc.
The present invention provides the application of a kind of ginsenoside Ppt compositions in preparation prevention, alleviation and/or treatment affective disorders disease medicament or health product on the other hand.
Wherein said affective disorders disease is a depression.
Wherein, described ginsenoside Ppt compositions is selected the pharmaceutically solvate of the acceptable salt of ginsenoside Ppt, ginsenoside Ppt.
Wherein, described ginsenoside Ppt compositions can be that ginsenoside Ppt and other antidepressant chemical compound are formed preferably ginseng's Saponin Rg1 and/or ginsenoside Rh1.
Another aspect of the invention provides the application of pharmaceutical composition in preparation prevention, alleviation and/or treatment affective disorders disease medicament or health product of a kind of ginsenoside of comprising Ppt.
Wherein said affective disorders disease is a depression.
Further aspect of the present invention provides a kind of nutrient and health food that is used to prevent depression and/or alleviate depression disease symptom, it is characterized in that comprising ginsenoside Ppt.
The present invention also provides a kind of method for the treatment of depression, comprise to the experimenter and treat the ginsenoside Ppt of effective dose and/or the pharmaceutical composition of ginsenoside Ppt, its treatment effective dose is Radix Ginseng saponin P pt0.5～4mg/kgd, be preferably ginsenoside Ppt0.1～3mg/kgd, more preferably ginsenoside Ppt01.5～2mg/kgd.
Unless otherwise indicated, term used herein " treatment effective dose " is for needing to produce the amount of drug of useful effect; " treatment effective dose " can be adjusted and change, and finally determined by the medical worker, and its factor of considering comprises the character and the order of severity of the ordinary circumstance such as character, the receiver's of route of administration and preparation body weight, age and the disease for the treatment of.
Compared with prior art, the present invention has following obvious advantage:
1, the present invention has excavated metabolite ginsenoside Ppt or its pharmaceutically acceptable salt or the new medical value of its solvate of ginsenoside Rg1, use it for depression, and can be prepared into the medicine or the health food of prevention, conditioning and/or treatment depression.
2, the present invention studies have shown that ginsenoside Ppt is an antidepressant drug behind the receptor, by activating the cAMP-PKA path, promotes the phosphorylation of brain district CREB and the expression of rise BDNF, prevention and treatment depression.Experimental results show that ginsenoside Ppt can significantly shorten mouse tail suspension dead time and forced swimming dead time, the antidepressant effect of prompting Radix Ginseng saponin P pt may be better than the positive drug paroxetine.
3, Radix Ginseng saponin P pt of the present invention safety is good, suits to take for a long time, can be to the treatment of the depression property nursed one's health.
4, Radix Ginseng saponin P pt of the present invention both can adopt the medicine of single component preparation prevention and treatment depression, again can with the common prescription of other active component (for example with chemical compounds such as peoniflorin, lactone glucoside of Radix Paeoniae, glycyrrhizic acids), prepare the antidepressant compound medicine of many target spots.
Description of drawings
Accompanying drawing 1 is the influence of Radix Ginseng saponin P pt to PC12 neurocyte phosphorylation CREB
Accompanying drawing 2 is the influence of Radix Ginseng saponin P pt to PC12 neurocyte BDNF
The specific embodiment mode
Below in conjunction with specific embodiment, further set forth the present invention.Be not used in but these embodiment only limit to the present invention is described and limit the scope of the invention.The experimental technique of unreceipted concrete experiment condition in the following example, usually according to normal condition, or the condition of advising according to manufacturer.
Below further set forth the beneficial effect of medicine of the present invention by testing example, these test the routine pharmacodynamics test that has comprised medicine of the present invention.
Embodiment 1 ginsenoside Ppt is to the influence of mouse tail suspension experiment
1.1 experiment material
The ICR mice, male, body weight 18～20g provides quality certification numbering: SCXK (capital) 2007-0003 by dimension tonneau China zoopery center.
Ginsenoside Ppt (purity＞98%), Jilin Agriculture University China enlightening bio tech ltd provides;
Paroxetine, Sino-America Tianjin Shike Pharmaceutical Co., Ltd.'s (lot number: 08030078);
JZ type 300g tonotransducer (Gaobeidian City newly navigate accumulation equipment company limited);
Medlab bio signal acquisition processing system (Nanjing is easily beautiful)
1.2 experimental technique and result
Normal mouse is divided into 5 groups at random by body weight, 20 every group, i.e. model group, positive drug paroxetine (3.5mg/kg/d), ginsenoside Ppt height (10mg/kg/d), low (5mg/kg/d) dosage group.Each is organized all by 0.2ml/10g body weight gastric infusion, successive administration 2 days.
Used immobilization with adhesive tape on the line of 100g tonotransducer mice tail end (at distance tail point 2cm place) in the 2nd day after the administration 1h, make it be the state of hanging by the feet, head is tested 2 animals from the about 15cm of laboratory table at every turn simultaneously, separates with cardboard each other.Transducer is connected to Medlab bio signal acquisition processing system, and behind the adaptation 2min, the result within the record 4min is converted into the time (s) with motionless state.
Experimental data represents that with X ± SD experimental result is carried out variance analysis with SPSS11.5 statistical software (available from U.S. SPSS Inc.).Experimental result sees Table 1.
Table 1 ginsenoside Ppt is to the influence of mouse tail suspension dead time (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group
Experimental result shows:
Ginsenoside Ppt high and low dose group and positive drug paroxetine group all can significantly shorten the mouse tail suspension dead time (comparing P＜0.01 with model group), and prompting Radix Ginseng saponin P pt has good antidepressant function.
Embodiment 2, ginsenoside Ppt are to the influence of mice forced swimming experiment
2.1 experiment material
The ICR mice, male, body weight 18～20g provides quality certification numbering: SCXK (capital) 2007-0003 by dimension tonneau China zoopery center.
Ginsenoside Ppt (purity＞98%), Jilin Agriculture University China enlightening bio tech ltd provides;
Paroxetine, Sino-America Tianjin Shike Pharmaceutical Co., Ltd.'s (lot number: 08030078);
Thermometer, stopwatch, glass jar, Plato's digital camera head, notebook computer.
2.2 experimental technique
Normal mouse is divided into 5 groups at random by body weight, 20 every group, i.e. model group, positive drug paroxetine (3.5mg/kg/d), ginsenoside Ppt height (10mg/kg/d), low (5mg/kg/d) dosage group.Each is organized all by 0.2ml/10g body weight gastric infusion, successive administration 2 days, and the blank group is given deionized water.
After the 2nd day administration 1h,, observe 6min, adapt to 2min, the accumulative total dead time (s) in the 4min of record back the single water vat of putting into 23 ± 2 ℃ of high 20cm, diameter 18cm, depth of water 10cm, water temperature of mice.
Data are represented with x ± s, handle with the SPSS13.0 statistical software, and with One-Way ANOVA method, homogeneity of variance is checked with LSD and SNK.Experimental result sees Table 2.
Table 2 ginsenoside Ppt is to the influence of mice forced swimming dead time (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group
Experimental result shows: ginsenoside Ppt high and low dose group and positive drug paroxetine group all can obviously shorten the mice forced swimming dead time (comparing P＜0.01 with model group), show that ginsenoside Ppt has stronger antidepressant effect.
Embodiment 3 ginsenoside Ppt are to the influence of monoamine neurotransmitter in the chronic stress rat brain
3.1 experiment material
Be subjected to reagent: ginsenoside Ppt (purity＞98%), Jilin Agriculture University China enlightening bio tech ltd supplies;
Positive drug: fluoxetine Hydrochloride (Fluoxetine, Prozac fluoxetine), gift comes Suzhou pharmaceutical Co. Ltd, lot number: the accurate word J20030017 of traditional Chinese medicines, the rat consumption is 2.5mg/kg.
Norepinephrine (NE, Serva company); Dopamine (DA, Fluka company); 5-hydroxy tryptamine (5-HT, Sigma company); 3,4-dihydroxyphenyl acetic acid (DOPAC, Sigma company); 3,4-dihydroxy benzylamine (DHBA, Sigma company), di-n-butylamine (Shanghai chemical reagent factory), D-8 ion-pairing agent (Tianjin chemical reagent two factories), methanol (top grade is pure, the Beijing Chemical Plant), other reagent is homemade analytical pure.
The SD rat, male, body weight 220～240g.Provide quality certification numbering: 2007-0001 by dimension tonneau China zoopery center.
The Waters510 pump, M464 electrochemical detector DL-822 chromatographic work station (Dalian Chemistry and Physics Institute chromatograph center), MSE150 type ultrasonic disintegrator
3.2 experimental technique
3.2.1 grouping and administration
The SD rat, 24h gives 1% sucrose water after prohibiting the water non-fasting, measures the consumption in the 1h.Be divided into 6 groups at random according to the sucrose water consumption, 12 every group, i.e. normal control group, model group, positive drug fluoxetine Hydrochloride group (2.5mg/kg/d), ginsenoside Ppt height (8.6mg/kg/d), low (4.3mg/kg/d) dosage group.Modeling is gastric infusion simultaneously, once a day, and successive administration 21 days.Each group claims body weight weekly one time all by the administration of 1.0ml/100g body weight.
3.2.2 modeling
6/cage of normal control group is raised, and normal diet drinking-water is not given any stimulation.
Other five groups, 1/cage is raised, and accepts 21 days unpredictable stress stimulation, comprising: frozen water swimming, baking the affected part after applying some drugs, the folder tail, the moist raising put upside down round the clock, and water etc. is prohibited in fasting.Give a kind of stimulation every group of every day at random.
Every kind stress concrete operation method:
(1) frozen water swimming: animal is put into the bucket that fills 4 ℃ of cold water (frozen water mixing), depth of water 15cm, the toe of rat just can touch drum head, behind the 5min animal is taken out.
(2) baking the affected part after applying some drugs: oven temperature transfers to 45 ℃ and fixes, and animal is put into baking oven, behind the 5min animal is taken out.
(3) folder tail: rat is put into fixedly cage, expose tail, clamp apart from root of the tail portion 1cm place (it is not excessive to exert oneself, rat is sent wail get final product), lasting 1min with mosquito forceps.
(4) the moist raising: mornings 8 point, in mouse cage, add 200ml water, change to 8 of morning next day.
(5) put upside down round the clock: mornings 8 point, rat is put into dark case, 8 illuminations that turn on the light in evening are to the next day of 8 points early.
(6) fasting: 24h fracture.
(7) prohibit water: 24h cuts off the water supply.
3.2.3 sample preparation and detection
The animal sacrificed by decapitation is peeled off brain rapidly on ice, get prefrontal cortex, and the postposition of weighing is put into-70 ℃ of refrigerators and is saved to mensuration after organizing and using the liquid nitrogen quick freezing in the cryovial.
According to the weight of cerebral tissue, the 0.1mol/L that adds pre-cooling crosses chloric acid (including 0.3mM EDTA disodium and 0.5mM sodium sulfite), and 2 μ g/ml DHBA are mixed with 800 μ L, ultrasonic homogenate, and the centrifugal 10min of 11000rpm, supernatant are used for neurotransmitter and measure.
Adopt high-efficient liquid phase chromatogram-electrochemical detector system (HPLC-ECD) to measure, chromatographic condition is: chromatographic column is 4 * 150mm, Nova-pak Cl8,5 μ m (filling of chromatograph center, Dalian); Mobile phase is 50mM citric acid-sodium acetate buffer PH3.5 (including 1.0mM B-8 ion-pairing agent, 1.8mM di-n-butylamine, 0.3mM EDTA disodium, 4% methanol), flow velocity 1.0mL/min, and the vitreous carbon working electrode, detection cell voltage is+0.75V; 3,4-dihydroxy benzylamine DHBA is an internal standard substance, and each key component is carried out quantitatively with internal standard method in the sample.
Detect data and represent with x ± s, with SPSS 13.0 software processes, with One-Way ANOVA method, testing result sees Table 9,10.
Table 3 ginsenoside Ppt is to the influence of norepinephrine in the chronic stress rat brain (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group.
Table 4 ginsenoside Ppt is to the influence of serotonin in the chronic stress rat brain (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group.
Experimental data in the table 3,4 shows that successive administration obviously reduced (P＜0.05) with monoamine neurotransmitter norepinephrine, 5-hydroxy tryptamine content in the blank group comparison model group rat brain after 21 days; With monoamine neurotransmitter norepinephrine, 5-hydroxy tryptamine content in model group comparison ginsenoside Ppt high dose group and the positive drug fluoxetine Hydrochloride group rat brain obviously raise (P＜0.05).
Monoamine transmitters in the brain as insufficiency of function such as norepinephrine, 5-hydroxy tryptamine and dopamine, causes the depression morbidity.The reason that causes depression in the time of the reserpine blood pressure lowering is exactly because reserpine makes due to norepinephrine in the presynaptic membrane vesicle exhausts.This experimentation shows that 5-hydroxy tryptamine, noradrenaline cellulose content obviously reduce in the chronic stress rat brain, and ginsenoside Ppt can significantly improve the content of 5-hydroxy tryptamine, norepinephrine in the brain.Pointing out above effect may be one of the important mechanisms of the antidepressant effect of ginsenoside Ppt.
Embodiment 4 ginsenoside Ppt are to the influence experiment of PC12 cells phosphorylation CREB
4.1 experiment material
Cell culture: the PC12 cell is purchased the cell centre in Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, cultivates in the RPMI1640 culture medium, wherein adds volume fraction and be 10% horse serum and volume fraction and be 5% hyclone, in 37 ℃, and 5%CO
2Cultivate in the incubator.
Ginsenoside Ppt: provide purity＞98% (be configured to aqueous solution, be stored in 4 ℃ of refrigerators standby) by Jilin Agriculture University China enlightening bio tech ltd;
Monoclonal P-CREB Ser133 antibody (Cell Signaling Technology company);
The super quick luminescent solution of ECL is Beijing Puli's lema gene company product;
Electrophresis apparatus and electrophoresis tank (Liuyi Instruments Plant, Beijing); Electroporation (Bio-Rad); Microplate reader (EL311sBIO-TEK INSTRUMENTS Inc.); Milli Q plus ultra-pure water system (Millipore); Homogenizer (Polytran, Sweden); ECL detection system (Japanese fuji).
4.2 experimental technique:
4.2.1PC12 cell dosage regimen: the trophophase PC12 cell of taking the logarithm is with 10
7Density is inoculated in 6 orifice plates, and treating to give after adherent in 24 hours Radix Ginseng saponin P pt stimulates, extract after 48 hours cell protein prepare protein sample and be stored in-20 ℃ stand-by.
4.2.2 ginsenoside Ppt is to the influence of PC12 cell P-CREB: adopt western blot method that PC12 cell P-CREB level is detected.
4.3 experimental result:
Ginsenoside Ppt sees accompanying drawing 1 to the influence of PC12 neurocyte phosphorylation CREB.
Experimental result shows: ginsenoside Ppt can promote the expression of PC12 endocellular phosphorus acidify CREB.
Embodiment 5 ginsenoside Ppt are to the influence experiment of PC12 cell BDNF
5.1 experiment material
Cell culture: the PC12 cell is purchased the cell centre in Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, cultivates in the RPMI1640 culture medium, wherein adds volume fraction and be 10% horse serum and volume fraction and be 5% hyclone, in 37 ℃, and 5%CO
2Cultivate in the incubator.
Ginsenoside Ppt: provide purity＞98% (be configured to aqueous solution, be stored in 4 ℃ of refrigerators standby) by Jilin Agriculture University China enlightening bio tech ltd;
Polyclone BDNF antibody, β-Actin antibody and anti-rabbit igg two anti-(Santa Cruz Biotechnology company);
The super quick luminescent solution of ECL is Beijing Puli's lema gene company product;
Electrophresis apparatus and electrophoresis tank (Liuyi Instruments Plant, Beijing); Electroporation (Bio-Rad); Microplate reader (EL311sBIO-TEK INSTRUMENTS Inc.); Milli Q plus ultra-pure water system (Millipore); Homogenizer (Polytran, Sweden); ECL detection system (Japanese fuji).
5.2 experimental technique:
5.2.1PC12 cell dosage regimen: the trophophase PC12 cell of taking the logarithm is with 10
7Density is inoculated in 6 orifice plates, and treating to give after adherent in 24 hours Radix Ginseng saponin P pt stimulates, extract after 48 hours cell protein prepare protein sample and be stored in-20 ℃ stand-by.
5.2.2 ginsenoside Ppt is to the influence of PC12 cell BDNF: adopt western blot method that PC12 cell BDNF level is detected.
5.3 experimental result:
Ginsenoside Ppt sees accompanying drawing 2 to the influence of PC12 neurocyte BDNF.
Experimental result shows that ginsenoside Ppt can promote the expression of BDNF in the PC12 neurocyte.
Claims (5)
1. the metabolite ginsenoside Ppt of ginsenoside Rg1 is used for preventing, alleviate and/or treat the application of the medicine or the health product of affective disorders disease or symptom in preparation.
2. application according to claim 1 is characterized in that described mental sickness is a depression.
3. application according to claim 1 and 2 is characterized in that described medicine is made up of ginsenoside Ppt and pharmaceutically acceptable carrier.
4. application according to claim 1 and 2 is characterized in that described medicine exists with forms such as tablet, capsule, pill, powder, granule, syrup, solution, injection, spray, aerosol, patches.
5. the medicine or the health product of a prevention, alleviation and/or treatment depression disease is characterized in that comprising ginsenoside Ppt or the compositions of ginsenoside Ppt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101075238A CN102145006A (en) | 2010-02-09 | 2010-02-09 | Depression resistance application of panaxoside Ppt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101075238A CN102145006A (en) | 2010-02-09 | 2010-02-09 | Depression resistance application of panaxoside Ppt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102145006A true CN102145006A (en) | 2011-08-10 |
Family
ID=44419608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101075238A Pending CN102145006A (en) | 2010-02-09 | 2010-02-09 | Depression resistance application of panaxoside Ppt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102145006A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895256A (en) * | 2006-06-09 | 2007-01-17 | 上海中药创新研究中心 | Use of 20(S)-protopanoxadiol in preparation of antidepressant medicine |
| WO2008155998A1 (en) * | 2007-06-21 | 2008-12-24 | Nagase & Co., Ltd. | Antianxiety/antidepressant agent |
-
2010
- 2010-02-09 CN CN2010101075238A patent/CN102145006A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895256A (en) * | 2006-06-09 | 2007-01-17 | 上海中药创新研究中心 | Use of 20(S)-protopanoxadiol in preparation of antidepressant medicine |
| WO2008155998A1 (en) * | 2007-06-21 | 2008-12-24 | Nagase & Co., Ltd. | Antianxiety/antidepressant agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102438630B (en) | Pharmaceutical composition for treating depression and preparative method and use thereof | |
| CN102038701B (en) | Anti-depression application of albiflorin | |
| CN105878322B (en) | It is a kind of to crystallize sunflower disk extract prepared by enzymatic isolation method and preparation method thereof | |
| KR102227117B1 (en) | Use of 2,3,5-Substituted Thiophene Compound for Prevention, Improvement or Treatment of Breast Cancer | |
| CN103989677A (en) | Use of demethyleneberberine in preparation of blood sugar-reduction drug | |
| CN103919775A (en) | Application of 9-demethylberberine in preparation of hpyerglycemic drug | |
| CN106822599A (en) | A kind of dendrobium loddigesii Rolfe extract and its anti-diabetes use | |
| CN106822166B (en) | A kind of drug for preventing and treating diabetes and hyperlipidemia and its application in pharmacy | |
| CN105853382B (en) | A kind of Li Gelieting oral disintegrating tablet and preparation method thereof | |
| KR20200052221A (en) | Composition for treating, alleviating or preventing pain comprising bupleuri radix extract or its ingredient | |
| CN109350632A (en) | A kind of Chinese medicine composition for antipyretic-antalgic | |
| CN102145006A (en) | Depression resistance application of panaxoside Ppt | |
| CN102342949B (en) | Application of phlorhizin in preparation of drug for treating hyperuricemia | |
| CN101152173A (en) | Use of liquiritigenin in preparing medicament for treating neurodegenerative diseases | |
| CN106943408B (en) | Application of tetramethyluric acid in preventing and treating diabetes | |
| CN101940585B (en) | Composite using orientin-2'-O-beta-L-galactoside as main component and application thereof | |
| AU2016256704B2 (en) | Pharmaceutical composition increasing cyclic AMP content and availability in vivo, and preparation method thereof | |
| CN107198692A (en) | Application of the Acankoreanogenia A in treatment diabetes medicament is prepared | |
| CN117180331B (en) | External antipyretic traditional Chinese medicine composition, preparation method and application thereof and antipyretic gel plaster | |
| CN106831667B (en) | 8-epi-Hypophyllin E and its derivative and its pharmaceutical composition and its application in pharmacy | |
| CN106620642A (en) | Western medicine composition for treating hyperglycemia | |
| CN105560313A (en) | Compound medicine prepared from Chinese St. John's wort herbs and carolina cranesbill herbs and used for treating diabetes and preparation method thereof | |
| CN104288370A (en) | Novel medicinal application of Sailuotong capsule | |
| Liu et al. | Exploring the scientific rationality of “Different dosage forms of the same prescription” base on Q-markers of pulvis and pill of Chuanxiong Chatiao Prescription | |
| Sun et al. | Skin irritation assessment and potential mechanism of Capparis spinosa L. fruits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110810 |